<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:13:49Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8018623" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8018623</identifier>
        <datestamp>2021-04-13</datestamp>
        <setSpec>plosone</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS One</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-id journal-id-type="pmc">plosone</journal-id>
              <journal-title-group>
                <journal-title>PLoS ONE</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1932-6203</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8018623</article-id>
              <article-id pub-id-type="pmcid">PMC8018623</article-id>
              <article-id pub-id-type="pmc-uid">8018623</article-id>
              <article-id pub-id-type="pmid">33798209</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pone.0247493</article-id>
              <article-id pub-id-type="publisher-id">PONE-D-20-32204</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Metabolism</subject>
                      <subj-group>
                        <subject>Metabolites</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Medical Conditions</subject>
                    <subj-group>
                      <subject>Infectious Diseases</subject>
                      <subj-group>
                        <subject>Viral Diseases</subject>
                        <subj-group>
                          <subject>Influenza</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Physical Sciences</subject>
                  <subj-group>
                    <subject>Chemistry</subject>
                    <subj-group>
                      <subject>Chemical Compounds</subject>
                      <subj-group>
                        <subject>Organic Compounds</subject>
                        <subj-group>
                          <subject>Amino Acids</subject>
                          <subj-group>
                            <subject>Aromatic Amino Acids</subject>
                            <subj-group>
                              <subject>Tryptophan</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Physical Sciences</subject>
                  <subj-group>
                    <subject>Chemistry</subject>
                    <subj-group>
                      <subject>Organic Chemistry</subject>
                      <subj-group>
                        <subject>Organic Compounds</subject>
                        <subj-group>
                          <subject>Amino Acids</subject>
                          <subj-group>
                            <subject>Aromatic Amino Acids</subject>
                            <subj-group>
                              <subject>Tryptophan</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Proteins</subject>
                      <subj-group>
                        <subject>Amino Acids</subject>
                        <subj-group>
                          <subject>Aromatic Amino Acids</subject>
                          <subj-group>
                            <subject>Tryptophan</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Lipids</subject>
                      <subj-group>
                        <subject>Sphingolipids</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Metabolism</subject>
                      <subj-group>
                        <subject>Metabolomics</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Metabolism</subject>
                      <subj-group>
                        <subject>Amino Acid Metabolism</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Lipids</subject>
                      <subj-group>
                        <subject>Glycerides</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Neurochemistry</subject>
                      <subj-group>
                        <subject>Neurotransmitters</subject>
                        <subj-group>
                          <subject>Biogenic Amines</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Neuroscience</subject>
                    <subj-group>
                      <subject>Neurochemistry</subject>
                      <subj-group>
                        <subject>Neurotransmitters</subject>
                        <subj-group>
                          <subject>Biogenic Amines</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Metabolite profiles associated with disease progression in influenza infection</article-title>
                <alt-title alt-title-type="running-head">Metabolites and influenza outcome</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0924-8745</contrib-id>
                  <name>
                    <surname>Wendt</surname>
                    <given-names>Chris H.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Project administration</role>
                  <role content-type="https://casrai.org/credit/">Supervision</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor001">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9913-3409</contrib-id>
                  <name>
                    <surname>Castro-Pearson</surname>
                    <given-names>Sandra</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Proper</surname>
                    <given-names>Jennifer</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pett</surname>
                    <given-names>Sarah</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Funding acquisition</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Griffin</surname>
                    <given-names>Timothy J.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff005">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7569-2740</contrib-id>
                  <name>
                    <surname>Kan</surname>
                    <given-names>Virginia</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff006">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Carbone</surname>
                    <given-names>Javier</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff007">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Koulouris</surname>
                    <given-names>Nikolaos</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff008">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Reilly</surname>
                    <given-names>Cavan</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Neaton</surname>
                    <given-names>James D.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Funding acquisition</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <collab>for the INSIGHT FLU003 Plus Study Group</collab>
                  <xref ref-type="author-notes" rid="fn001">
                    <sup>¶</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>Pulmonary, Allergy, Critical Care and Sleep Medicine Section, Minneapolis Veterans Administration Health Care System, Minneapolis, Minnesota, United States of America</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America</addr-line>
              </aff>
              <aff id="aff003">
                <label>3</label>
                <addr-line>Division of Biostatistics, University of Minnesota, Minneapolis, Minnesota, United States of America</addr-line>
              </aff>
              <aff id="aff004">
                <label>4</label>
                <addr-line>Medical Research Council Clinical Trials Unit, University College London, London, United Kingdom</addr-line>
              </aff>
              <aff id="aff005">
                <label>5</label>
                <addr-line>Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota, Minneapolis, MN, United States of America</addr-line>
              </aff>
              <aff id="aff006">
                <label>6</label>
                <addr-line>Infectious Diseases Section, Veterans Administration Health Care System, and George Washington University, Washington, DC, United States of America</addr-line>
              </aff>
              <aff id="aff007">
                <label>7</label>
                <addr-line>Clinical Immunology Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain</addr-line>
              </aff>
              <aff id="aff008">
                <label>8</label>
                <addr-line>Respiratory Medicine Dept, National and Kapodistrian University of Athens Medical School, Athens, Greece</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Ratnasekhar</surname>
                    <given-names>Ch</given-names>
                  </name>
                  <role>Editor</role>
                  <xref ref-type="aff" rid="edit1"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>Queen’s University Belfast, UNITED KINGDOM</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p><bold>Competing Interests: </bold>I have read the journal’s policy and the authors of this manuscript have the following competing interests: The views expressed in this article are those of the authors and do not reflect the views of the US Government, the National Institutes of Health, the Department of Veterans Affairs, the funders, or any of the authors’ affiliated academic institutions. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</p>
                </fn>
                <fn fn-type="other" id="fn001">
                  <p>¶ Membership of the INSIGHT FLU003 Plus Study Group is listed in the Acknowledgments.</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>wendt005@umn.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>2</day>
                <month>4</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2021</year>
              </pub-date>
              <volume>16</volume>
              <issue>4</issue>
              <elocation-id>e0247493</elocation-id>
              <history>
                <date date-type="received">
                  <day>13</day>
                  <month>10</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>5</day>
                  <month>1</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <license xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">
                  <license-p>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0</ext-link> public domain dedication.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="pone.0247493.pdf"/>
              <abstract>
                <sec id="sec001">
                  <title>Background</title>
                  <p>We performed metabolomic profiling to identify metabolites that correlate with disease progression and death.</p>
                </sec>
                <sec id="sec002">
                  <title>Methods</title>
                  <p>We performed a study of adults hospitalized with Influenza A(H1N1)pdm09. Cases (n = 32) were defined by a composite outcome of death or transfer to the intensive care unit during the 60-day follow-up period. Controls (n = 64) were survivors who did not require transfer to the ICU. Four hundred and eight metabolites from eight families were measured on plasma sample at enrollment using a mass spectrometry based Biocrates platform. Conditional logistic regression was used to summarize the association of the individual metabolites and families with the composite outcome and its major two components.</p>
                </sec>
                <sec id="sec003">
                  <title>Results</title>
                  <p>The ten metabolites with the strongest association with disease progression belonged to five different metabolite families with sphingolipids being the most common. The acylcarnitines, glycerides, sphingolipids and biogenic metabolite families had the largest odds ratios based on the composite endpoint. The tryptophan odds ratio for the composite is largely associated with death (OR 17.33: 95% CI, 1.60–187.76).</p>
                </sec>
                <sec id="sec004">
                  <title>Conclusions</title>
                  <p>Individuals that develop disease progression when infected with Influenza H1N1 have a metabolite signature that differs from survivors. Low levels of tryptophan had a strong association with death.</p>
                </sec>
                <sec id="sec005">
                  <title>Registry</title>
                  <p>ClinicalTrials.gov Identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01056185">NCT01056185</ext-link></p>
                </sec>
              </abstract>
              <funding-group>
                <award-group id="award001">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000060</institution-id>
                      <institution>National Institute of Allergy and Infectious Diseases</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>HHSN261200800001E</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Neaton</surname>
                      <given-names>James D.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award002">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000060</institution-id>
                      <institution>National Institute of Allergy and Infectious Diseases</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>HHSN261201500003I</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Neaton</surname>
                      <given-names>James D.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award003">
                  <funding-source>
                    <institution>Department of Veterans Affairs Office of Research and Development</institution>
                  </funding-source>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0924-8745</contrib-id>
                    <name>
                      <surname>Wendt</surname>
                      <given-names>Chris H.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award004">
                  <funding-source>
                    <institution>Department of Veterans Affairs Office of Research and Development</institution>
                  </funding-source>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7569-2740</contrib-id>
                    <name>
                      <surname>Kan</surname>
                      <given-names>Virginia</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award005">
                  <funding-source>
                    <institution>National Institute of Allergy and Infectious Diseases</institution>
                  </funding-source>
                  <award-id>HHSN261200800001E</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Pett</surname>
                      <given-names>Sarah</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award006">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000060</institution-id>
                      <institution>National Institute of Allergy and Infectious Diseases</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>HHSN261201500003I</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Pett</surname>
                      <given-names>Sarah</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award007">
                  <funding-source>
                    <institution>University of New South Wales</institution>
                  </funding-source>
                  <principal-award-recipient>
                    <name>
                      <surname>Pett</surname>
                      <given-names>Sarah</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <funding-statement>This work was supported by a Subcontract award 13XS134 under Leidos Biomed's Prime Contract [HHSN261200800001E and HHSN261201500003I], NCI/NIAID to The INSIGHT FLU 003 study awarded to JN. Protected research time was provided by the Department of Veterans Affairs Office of Research and Development to CW and VK. This work was also supported by a subcontract from University Minnesota [HHSN261200800001E and HHSN261201500003I], NCI/NIAID and protected time from the University of New South Wales awarded to SP.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="1"/>
                <table-count count="4"/>
                <page-count count="12"/>
              </counts>
              <custom-meta-group>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>All relevant data are within the paper and its <xref ref-type="sec" rid="sec015">Supporting Information</xref> files.</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>All relevant data are within the paper and its <xref ref-type="sec" rid="sec015">Supporting Information</xref> files.</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec006">
              <title>Introduction</title>
              <p>The INSIGHT Influenza Hospitalization study (FLU 003) is an international observational cohort study that was launched in 2009 to characterize A(H1N1)pdm09 infection. Previous studies from this cohort identified baseline elevations of biomarkers associated with inflammation, coagulation and/or immune function as predictors for disease progression [<xref rid="pone.0247493.ref001" ref-type="bibr">1</xref>]. In addition, for the same cases and controls considered in this investigation, we previously carried out a targeted analysis for 2 specific metabolites, tryptophan (T) and kynurenine (K) and found significantly elevated KT ratio among cases, consistent with tryptophan catabolism, and found an elevated KT ratio was associated with worse clinical outcomes following hospitalization [<xref rid="pone.0247493.ref002" ref-type="bibr">2</xref>]. Tryptophan catabolism is also reported in influenza associated encephalopathy where metabolic profiling identified additional metabolite biomarkers [<xref rid="pone.0247493.ref003" ref-type="bibr">3</xref>]. These findings motivated an investigation of a larger number of metabolites using our same case:control design.</p>
              <p>Metabolomics is the systematic identification, quantification and characterization of metabolites, the products of metabolism, within an organism or biological sample. Metabolomics has emerged as a useful tool to identify biomarkers of disease and identify putative pathways of disease [<xref rid="pone.0247493.ref004" ref-type="bibr">4</xref>]. Influenza infection is a systemic infection with broad physiological ramifications. These ramifications include the metabolome, which is perturbed in both animal and cellular models of influenza infection [<xref rid="pone.0247493.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0247493.ref006" ref-type="bibr">6</xref>]. Recent studies, including our own, have demonstrated perturbations in the metabolome in influenza infection in humans [<xref rid="pone.0247493.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0247493.ref007" ref-type="bibr">7</xref>]. In addition to tryptophan catabolism, broad perturbations that include metabolite families such as purines, pyrimidines, acylcarnitines, fatty acids, amino acids, glucocorticoids, sphingolipids, and phospholipids are found in animal models of influenza pneumonia [<xref rid="pone.0247493.ref008" ref-type="bibr">8</xref>]. Using nuclear magnetic resonance technology, human studies have identified alterations in amino acids, sugars and other small molecules in influenza associated with lung injury and pneumonia [<xref rid="pone.0247493.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0247493.ref010" ref-type="bibr">10</xref>]. NMR has the advantage of using a targeted approach; however, it has limitations in metabolite profiling [<xref rid="pone.0247493.ref004" ref-type="bibr">4</xref>]. In this study, we used a targeted, quantitative mass spectrometry-based approach to measure 408 metabolites across several metabolome families and identify metabolites associated with poor clinical outcomes, death or transfer to intensive care in patients hospitalized for influenza A(H1N1)pdm09 infection.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec007">
              <title>Methods</title>
              <sec id="sec008">
                <title>Study design and objectives</title>
                <p>FLU 003 is an ongoing, international observational study of adults hospitalized with influenza that began in 2009 following the pandemic infection with the influenza A(H1N1)pdm09 virus (ClinicalTrials.gov Identifier: NCT01056185). This was a matched nested case-control study whose results were previously reported [<xref rid="pone.0247493.ref002" ref-type="bibr">2</xref>]. Cases (n = 32) were FLU 003 patients with PCR-confirmed influenza A(H1N1)pdm09 virus with a poor outcome following hospitalization defined as a composite outcome of death or transfer from the general ward to the intensive care unit (ICU) during the 60-day follow-up period after enrollment. Controls (n = 64) had PCR-confirmed influenza A(H1N1)pdm09 virus, survived the 60-day follow-up period, were not transferred to the ICU, and were matched on age (+/- 4 years) and gender. The objective of this exploratory study was to determine whether metabolic profiling would identify metabolomic families and/or specific metabolites that differed between those with a poor outcome (cases) compared to controls.</p>
              </sec>
              <sec id="sec009">
                <title>Ethics statement</title>
                <p>The FLU 003 protocol and information statement and consent form were approved by both the local institutional ethics committees/review boards of the participant sites and the ethics committee of the Sponsor of this study, the University of Minnesota. All participants or their representatives (when participants were unable to consent for themselves, and where the ethics permission allowed consent by a third party) provided written informed consent prior to their enrollment.</p>
              </sec>
              <sec id="sec010">
                <title>Mass Spectrometry (MS) analysis</title>
                <p>At study enrollment, blood was drawn into EDTA tubes and plasma was processed within 4 hours as previously described [<xref rid="pone.0247493.ref002" ref-type="bibr">2</xref>]. All plasma samples used in this analysis had undergone two freeze-thaw cycles. For metabolite identification, 10μl of plasma was manually loaded onto a Biocrates Life Sciences Absolute IDQ p400 HR (Biocrates Life Sciences catalog number 21018) following the manufacturer’s instructions. Analysis was performed on a Thermo Scientific, Q Exactive TM, Hybrid Quadrupole-Orbitrap TM, mass spectrometer equipped with a Thermo Scientific Ultimate 3000 UHPLC equipped with an autosampler. Sample metabolite quantification was performed with the integrated MetIDQ Biocrates software [<xref rid="pone.0247493.ref011" ref-type="bibr">11</xref>]. The Biocrates platform contains standards for eight families of metabolites for a total of 408 individual metabolites. Internal controls are incorporated for normalization between plates. The limit of detection (LOD) for each metabolite is provided by the Biocrates manufacturer and is calculated by Met/DQ<sup>TM</sup> and is defined as three times the background noise level. Families (number of metabolites) measured included: acylcarnitines (55), amino acids (21), biogenic amines (21), monosaccharide (1), di- and tri- glycerides (60), phospholipids (lysophosphatidylcholines and phosphatidylcholines) (196), sphingolipids (ceramides and sphingomyelins) (40) and cholesteryl esters (14) (S1 Table in <xref ref-type="supplementary-material" rid="pone.0247493.s001">S1 Appendix</xref>).</p>
              </sec>
              <sec id="sec011">
                <title>Statistical methods</title>
                <p>This study used the same cases and controls from our previous study [<xref rid="pone.0247493.ref002" ref-type="bibr">2</xref>]. Descriptive statistics were used to summarize the baseline characteristics of cases and controls. Metabolites with values below LOD in both the case and control groups that were present in 10% or more subjects were removed from consideration prior to analysis (S1 Table in <xref ref-type="supplementary-material" rid="pone.0247493.s001">S1 Appendix</xref>). Values that fell below the LOD for the remaining 188 metabolites were imputed with half of their corresponding LOD. One metabolite was further removed from analysis due to lack of variability that precluded the creation of tertiles. Conditional logistic regression that accounted for the matching by age and gender was used to summarize the association of the metabolite families and 187 individual metabolites with the composite outcome, death and transfer to the ICU. All models were adjusted for duration of symptoms at enrollment, which was significantly associated with the composite outcome in univariate analyses of potential confounding factors.</p>
                <p>For analyses by metabolite family, a new covariate was created by summing the standardized values of metabolites, which had mean 0 and standard deviation 1 across all subjects, from the same family. If individual metabolites in a family were associated with the composite outcome in a similar manner, we reasoned that such an analysis would provide improved power compared to a study of the individual metabolite. The analyses by family also provide a means of controlling for type 1 error.</p>
                <p>As a first step, we investigated kynurenine and tryptophan concentrations that were previously reported but with different laboratory methods [<xref rid="pone.0247493.ref002" ref-type="bibr">2</xref>]. Next we studied metabolite families and individual metabolites and focused our discussion on associations with p&lt;0.01 to provide some control of type 1 error. P-values cited are based on models that use continuous variables for the metabolite or family covariates. Odds ratios cited compare the upper and lower tertiles and 95% confidence intervals (CIs) are given.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec012">
              <title>Results</title>
              <p>Thirty-two participants met our case definition, of whom 22 died and 10 required transfer to the ICU during the follow-up period. Two controls were available for all cases that were matched for sex and did not differ significantly for race, smoking status or presence of underlying lung disease. In addition to matching factors, since influenza is a respiratory illness, we considered two potential confounders for disease progression: days since onset of influenza symptoms and history of lung disease (COPD and/or asthma) at the time of enrollment. Cases had been symptomatic for a median of eight days, whereas controls had been symptomatic for a median of six days (p = 0.04 for the difference) (<xref rid="pone.0247493.t001" ref-type="table">Table 1</xref>). Furthermore, 19% and 22% of cases and controls reported lung disease at time of enrollment, respectively (p = 0.70 for the difference) (<xref rid="pone.0247493.t001" ref-type="table">Table 1</xref>). Duration of symptoms was also significantly associated with the composite outcome and therefore included in subsequent conditional logistic regression analyses.</p>
              <table-wrap id="pone.0247493.t001" orientation="portrait" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pone.0247493.t001</object-id>
                <label>Table 1</label>
                <caption>
                  <title>Clinical characteristics.</title>
                </caption>
                <alternatives>
                  <graphic id="pone.0247493.t001g" xlink:href="pone.0247493.t001"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="center" rowspan="1" colspan="1"/>
                        <th align="center" rowspan="1" colspan="1">Case (n = 32)</th>
                        <th align="center" rowspan="1" colspan="1">Control (n = 64)</th>
                        <th align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <th align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1"/>
                        <th align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">No. (%) or Median (25th,75th %)</th>
                        <th align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">No. (%) or Median (25th,75th %)</th>
                        <th align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">p-value<xref ref-type="table-fn" rid="t001fn002"><sup>b</sup></xref></th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>Female<xref ref-type="table-fn" rid="t001fn001"><sup>a</sup></xref></bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">13 (41)</td>
                        <td align="center" rowspan="1" colspan="1">26 (41)</td>
                        <td align="center" rowspan="1" colspan="1">-</td>
                      </tr>
                      <tr>
                        <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">
                          <bold>Age<xref ref-type="table-fn" rid="t001fn001"><sup>a</sup></xref></bold>
                        </td>
                        <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">52 (41, 60)</td>
                        <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">53 (40, 60)</td>
                        <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">-</td>
                      </tr>
                      <tr>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>Non-white race</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">7 (22)</td>
                        <td align="center" rowspan="1" colspan="1">13 (20)</td>
                        <td align="center" rowspan="1" colspan="1">0.84</td>
                      </tr>
                      <tr>
                        <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">
                          <bold>Smoker</bold>
                        </td>
                        <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">10 (36)</td>
                        <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">22 (34)</td>
                        <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">0.86</td>
                      </tr>
                      <tr>
                        <td align="center" rowspan="1" colspan="1">
                          <bold>Days since onset of influenza symptoms</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">8 (6, 10)</td>
                        <td align="center" rowspan="1" colspan="1">6 (4, 7)</td>
                        <td align="center" rowspan="1" colspan="1">0.04</td>
                      </tr>
                      <tr>
                        <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">
                          <bold>Lung Disease</bold>
                        </td>
                        <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">6 (19)</td>
                        <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">14 (22)</td>
                        <td align="center" style="background-color:#F2F2F2" rowspan="1" colspan="1">0.70</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="t001fn001">
                    <p><sup>a</sup>Matching factor</p>
                  </fn>
                  <fn id="t001fn002">
                    <p><sup>b</sup>Univariate conditional logistic</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>In a previous publication we reported tryptophan and kynurenine concentrations using different methods, specifically single reaction monitoring with MS/MS [<xref rid="pone.0247493.ref002" ref-type="bibr">2</xref>]. For this analysis using the Biocrates platform with metabolite standards we performed adjusted conditional logistic regressions for kynurenine, tryptophan, and the KT ratio, the latter as a surrogate for tryptophan catabolism, to validate our previous findings (<xref rid="pone.0247493.t002" ref-type="table">Table 2</xref>). This analysis was then repeated after dividing the data into fatal and nonfatal cases, along with their matched controls, to determine if there were any associations with the mortality component of the composite outcome (<xref rid="pone.0247493.t002" ref-type="table">Table 2</xref>). For comparison purposes, we display the inverse odds ratio for tryptophan, i.e., those comparing the lower tertile to the upper tertile. The odds ratios (cases vs. controls) for kynurenine, tryptophan, and the KT ratio are, respectively, 2.96 (95% CI, 0.91–9.60), 3.34 (95% CI, 0.91–12.23), and 2.61 (95% CI, 0.81–8.39).</p>
              <table-wrap id="pone.0247493.t002" orientation="portrait" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pone.0247493.t002</object-id>
                <label>Table 2</label>
                <caption>
                  <title>Conditional logistic regression results for kynurenine, tryptophan, and the KT ratio.</title>
                </caption>
                <alternatives>
                  <graphic id="pone.0247493.t002g" xlink:href="pone.0247493.t002"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left" rowspan="1" colspan="1"> </th>
                        <th align="left" colspan="3" rowspan="1">Composite Endpoint</th>
                        <th align="left" colspan="3" rowspan="1">Mortality Endpoint</th>
                        <th align="left" colspan="3" rowspan="1">ICU Transfer Endpoint</th>
                      </tr>
                      <tr>
                        <th align="left" rowspan="1" colspan="1"/>
                        <th align="center" rowspan="1" colspan="1">OR</th>
                        <th align="center" rowspan="1" colspan="1">95% CI</th>
                        <th align="center" rowspan="1" colspan="1">P-value<xref ref-type="table-fn" rid="t002fn003"><sup>3</sup></xref></th>
                        <th align="center" rowspan="1" colspan="1">OR</th>
                        <th align="center" rowspan="1" colspan="1">95% CI</th>
                        <th align="center" rowspan="1" colspan="1">P-value<xref ref-type="table-fn" rid="t002fn003"><sup>3</sup></xref></th>
                        <th align="center" rowspan="1" colspan="1">OR</th>
                        <th align="center" rowspan="1" colspan="1">95% CI</th>
                        <th align="center" rowspan="1" colspan="1">P-value<xref ref-type="table-fn" rid="t002fn003"><sup>3</sup></xref></th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">KYN<xref ref-type="table-fn" rid="t002fn001"><sup>1</sup></xref></td>
                        <td align="center" rowspan="1" colspan="1">2.96</td>
                        <td align="center" rowspan="1" colspan="1">0.91–9.60</td>
                        <td align="center" rowspan="1" colspan="1">0.005</td>
                        <td align="center" rowspan="1" colspan="1">3.11</td>
                        <td align="center" rowspan="1" colspan="1">0.73–13.37</td>
                        <td align="center" rowspan="1" colspan="1">0.008</td>
                        <td align="center" rowspan="1" colspan="1">3.17</td>
                        <td align="center" rowspan="1" colspan="1">0.35–28.45</td>
                        <td align="center" rowspan="1" colspan="1">0.513</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">TRP<xref ref-type="table-fn" rid="t002fn002"><sup>2</sup></xref></td>
                        <td align="center" rowspan="1" colspan="1">3.34</td>
                        <td align="center" rowspan="1" colspan="1">0.91–12.23</td>
                        <td align="center" rowspan="1" colspan="1">0.032</td>
                        <td align="center" rowspan="1" colspan="1">17.33</td>
                        <td align="center" rowspan="1" colspan="1">1.60–187.76</td>
                        <td align="center" rowspan="1" colspan="1">0.013</td>
                        <td align="center" rowspan="1" colspan="1">0.21</td>
                        <td align="center" rowspan="1" colspan="1">0.02–2.70</td>
                        <td align="center" rowspan="1" colspan="1">0.356</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">KT Ratio<xref ref-type="table-fn" rid="t002fn001"><sup>1</sup></xref></td>
                        <td align="center" rowspan="1" colspan="1">2.61</td>
                        <td align="center" rowspan="1" colspan="1">0.81–8.39</td>
                        <td align="center" rowspan="1" colspan="1">0.010</td>
                        <td align="center" rowspan="1" colspan="1">3.11</td>
                        <td align="center" rowspan="1" colspan="1">0.73–13.37</td>
                        <td align="center" rowspan="1" colspan="1">0.014</td>
                        <td align="center" rowspan="1" colspan="1">1.86</td>
                        <td align="center" rowspan="1" colspan="1">0.25–13.85</td>
                        <td align="center" rowspan="1" colspan="1">0.580</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="t002fn001">
                    <p><sup>1</sup>Tertile 3 vs. Tertile 1 Odds Ratio</p>
                  </fn>
                  <fn id="t002fn002">
                    <p><sup>2</sup>Tertile 1 vs. Tertile 3 Odds Ratio</p>
                  </fn>
                  <fn id="t002fn003">
                    <p><sup>3</sup>P-values obtained from models with continuous covariates</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>When restricted to either fatal or nonfatal cases, the odds ratios for kynurenine and the KT ratio were similar to the odds ratios for the composite endpoint. In contrast, the tryptophan odds ratio for the composite endpoint appears to be largely determined by the death component. New for this analysis, we found among fatal and nonfatal cases the tryptophan odds ratios were 17.33 (95% CI, 1.60–187.76) and 0.21 (95% CI, 0.02–2.70), respectively. A graphical depiction of the relationships between mortality and the kynurenine and tryptophan tertiles can be seen in S1 Fig in <xref ref-type="supplementary-material" rid="pone.0247493.s001">S1 Appendix</xref>. Although these results are relatively imprecise due to the limited sample size, there is a strong negative association between mortality and the tryptophan tertiles consistent with our previous findings.</p>
              <p>The Biocrates platform contains metabolites from eight major metabolite families. <xref rid="pone.0247493.t003" ref-type="table">Table 3</xref> displays the results for the adjusted conditional logistic regression by metabolite family for the composite endpoint and the restricted fatal and nonfatal datasets. The acylcarnitines, glycerides, sphingolipids, and biogenic amines had the strongest odds ratios in the analysis based on the composite endpoint. For the acylcarnitines and glycerides, the odds ratios for disease progression were 3.99 (95% CI, 1.03–15.42) and 3.69 (95% CI, 1.08–12.61), respectively. Because these odds ratios did not change substantially when restricted to either fatal or nonfatal cases, the simplification of the composite endpoint did not appear to have much influence on the odds ratios for these two families.</p>
              <table-wrap id="pone.0247493.t003" orientation="portrait" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pone.0247493.t003</object-id>
                <label>Table 3</label>
                <caption>
                  <title>Conditional logistic regression results by metabolite family after adjusting for duration of symptoms.</title>
                </caption>
                <alternatives>
                  <graphic id="pone.0247493.t003g" xlink:href="pone.0247493.t003"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left" rowspan="1" colspan="1"> </th>
                        <th align="left" colspan="3" rowspan="1">Composite Endpoint</th>
                        <th align="left" colspan="3" rowspan="1">Mortality Endpoint</th>
                        <th align="left" colspan="3" rowspan="1">ICU Transfer Endpoint</th>
                      </tr>
                      <tr>
                        <th align="left" rowspan="1" colspan="1"/>
                        <th align="center" rowspan="1" colspan="1">OR</th>
                        <th align="center" rowspan="1" colspan="1">95% CI</th>
                        <th align="center" rowspan="1" colspan="1">P-value<sup>3</sup></th>
                        <th align="center" rowspan="1" colspan="1">OR</th>
                        <th align="center" rowspan="1" colspan="1">95% CI</th>
                        <th align="center" rowspan="1" colspan="1">P-value<sup>3</sup></th>
                        <th align="center" rowspan="1" colspan="1">OR</th>
                        <th align="center" rowspan="1" colspan="1">95% CI</th>
                        <th align="center" rowspan="1" colspan="1">P-value<sup>3</sup></th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Acylcarnitines</td>
                        <td align="center" rowspan="1" colspan="1">3.99</td>
                        <td align="center" rowspan="1" colspan="1">1.03–15.42</td>
                        <td align="center" rowspan="1" colspan="1">0.009</td>
                        <td align="center" rowspan="1" colspan="1">4.99</td>
                        <td align="center" rowspan="1" colspan="1">0.77–32.25</td>
                        <td align="center" rowspan="1" colspan="1">0.010</td>
                        <td align="center" rowspan="1" colspan="1">3.08</td>
                        <td align="center" rowspan="1" colspan="1">0.28–34.34</td>
                        <td align="center" rowspan="1" colspan="1">0.546</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Amino Acids</td>
                        <td align="center" rowspan="1" colspan="1">1.08</td>
                        <td align="center" rowspan="1" colspan="1">0.35–3.34</td>
                        <td align="center" rowspan="1" colspan="1">0.016</td>
                        <td align="center" rowspan="1" colspan="1">0.49</td>
                        <td align="center" rowspan="1" colspan="1">0.11–2.10</td>
                        <td align="center" rowspan="1" colspan="1">0.053</td>
                        <td align="center" rowspan="1" colspan="1">5.38</td>
                        <td align="center" rowspan="1" colspan="1">0.63–46.24</td>
                        <td align="center" rowspan="1" colspan="1">0.104</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Biogenic Amines</td>
                        <td align="center" rowspan="1" colspan="1">2.21</td>
                        <td align="center" rowspan="1" colspan="1">0.73–6.68</td>
                        <td align="center" rowspan="1" colspan="1">0.007</td>
                        <td align="center" rowspan="1" colspan="1">1.94</td>
                        <td align="center" rowspan="1" colspan="1">0.49–7.70</td>
                        <td align="center" rowspan="1" colspan="1">0.009</td>
                        <td align="center" rowspan="1" colspan="1">3.60</td>
                        <td align="center" rowspan="1" colspan="1">0.43–30.35</td>
                        <td align="center" rowspan="1" colspan="1">0.603</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Phospholipids</td>
                        <td align="center" rowspan="1" colspan="1">0.77</td>
                        <td align="center" rowspan="1" colspan="1">0.25–2.40</td>
                        <td align="center" rowspan="1" colspan="1">0.076</td>
                        <td align="center" rowspan="1" colspan="1">0.98</td>
                        <td align="center" rowspan="1" colspan="1">0.23–4.30</td>
                        <td align="center" rowspan="1" colspan="1">0.126</td>
                        <td align="center" rowspan="1" colspan="1">0.56</td>
                        <td align="center" rowspan="1" colspan="1">0.08–3.65</td>
                        <td align="center" rowspan="1" colspan="1">0.465</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Sphingolipids</td>
                        <td align="center" rowspan="1" colspan="1">0.27</td>
                        <td align="center" rowspan="1" colspan="1">0.07–1.13</td>
                        <td align="center" rowspan="1" colspan="1">0.016</td>
                        <td align="center" rowspan="1" colspan="1">0.07</td>
                        <td align="center" rowspan="1" colspan="1">0.01–0.83</td>
                        <td align="center" rowspan="1" colspan="1">0.021</td>
                        <td align="center" rowspan="1" colspan="1">1.10</td>
                        <td align="center" rowspan="1" colspan="1">0.13–9.26</td>
                        <td align="center" rowspan="1" colspan="1">0.551</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Cholesterol Esters</td>
                        <td align="center" rowspan="1" colspan="1">0.51</td>
                        <td align="center" rowspan="1" colspan="1">0.14–1.86</td>
                        <td align="center" rowspan="1" colspan="1">0.054</td>
                        <td align="center" rowspan="1" colspan="1">0.25</td>
                        <td align="center" rowspan="1" colspan="1">0.04–1.66</td>
                        <td align="center" rowspan="1" colspan="1">0.073</td>
                        <td align="center" rowspan="1" colspan="1">1.02</td>
                        <td align="center" rowspan="1" colspan="1">0.10–10.20</td>
                        <td align="center" rowspan="1" colspan="1">0.606</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Glycerides</td>
                        <td align="center" rowspan="1" colspan="1">3.69</td>
                        <td align="center" rowspan="1" colspan="1">1.08–12.61</td>
                        <td align="center" rowspan="1" colspan="1">0.020</td>
                        <td align="center" rowspan="1" colspan="1">3.84</td>
                        <td align="center" rowspan="1" colspan="1">0.80–18.47</td>
                        <td align="center" rowspan="1" colspan="1">0.039</td>
                        <td align="center" rowspan="1" colspan="1">4.00</td>
                        <td align="center" rowspan="1" colspan="1">0.48–33.03</td>
                        <td align="center" rowspan="1" colspan="1">0.497</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="t003fn001">
                    <p><sup>1</sup> P-values obtained from models with continuous covariates</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>Acylcarnitines are also known to be associated with both insulin resistance and sepsis. We therefore evaluated the association of diabetes and sepsis with the composite outcome and acylcarnitine levels. The presence of diabetes was found to be associated with the composite outcome (OR, 5.58; 95% CI, 1.16–36.10; p = 0.014) whereas this was not observed with sepsis (OR, 2.09; 95% CI, 0.26–16.54; p = 0.397). A Wilcoxon rank sum test found no significant differences in acylcarnitine levels based on diabetes (median difference, -0.285; 95% CI, -5.48–4.97; p = 0.95).</p>
              <p>The odds ratios varied for the sphingolipids and biogenic amine metabolite families. While the odds ratio for the composite endpoint for the biogenic amines was 2.21 (95% CI, 0.73–6.68), this value decreased to 1.94 (95% CI, 0.49–7.70) for fatal cases and notably increased to 3.60 (95% CI, 0.43–30.35) for nonfatal cases. Similarly, while the odds ratio for the composite endpoint for the sphingolipids was 0.27 (95% CI, 0.07–1.13; inverse OR, 3.70), this value decreased among fatal cases (OR, 0.07; 95% CI, 0.01–0.83; inverse OR, 14.29) and increased among nonfatal cases (OR, 1.10; 95% CI, 0.13–9.26; inverse OR, 0.98). As TNF-α can stimulate sphingolipid levels [<xref rid="pone.0247493.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0247493.ref013" ref-type="bibr">13</xref>], we performed a Wilcoxon rank sum test for our case:control study and found no significant differences in TNF-α levels based on the composite endpoint (median difference, 1.940; 95% CI, -0.300–4.270; p = 0.078); however, there was an association when restricted to mortality (median difference, 3.810; 95% CI, 0.860–7.860; p = 0.011). TNF-α levels were also found to be associated with sphingolipids with a Pearson’s correlation coefficient of -0.205 (95% CI, -0.390- -0.005; p = 0.045).</p>
              <p><xref rid="pone.0247493.t004" ref-type="table">Table 4</xref> shows the results for the adjusted conditional logistic regression for the 187 individual metabolites included in the analysis. The odds ratios comparing those in the upper tertile to those in the lower tertile are displayed for the ten metabolites found to have the strongest association with the composite outcome. Inverse odds ratios are provided so that metabolites with odds ratios above and below one can be effectively compared. For instance, the adjusted odds ratio comparing those in the upper vs. lower tertile for the triglyceride TG.48.3 and sphingomyelin SM.38.1 were, respectively, 10.79 (95% CI, 2.11–55.27) and 0.10 (95% CI, 0.02–0.63). Given the inverse odds ratio for SM.38.1 comparing those in the lower vs. upper tertile is 10.00, we note that TG.48.3 has a slightly stronger association with case-control status than SM.38.1.</p>
              <table-wrap id="pone.0247493.t004" orientation="portrait" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pone.0247493.t004</object-id>
                <label>Table 4</label>
                <caption>
                  <title>Ten strongest odds ratios comparing the upper vs. lower tertile after adjusting for duration of symptoms and matching factors.</title>
                </caption>
                <alternatives>
                  <graphic id="pone.0247493.t004g" xlink:href="pone.0247493.t004"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left" rowspan="1" colspan="1">Metabolite</th>
                        <th align="center" rowspan="1" colspan="1">Odds Ratio (OR)</th>
                        <th align="center" rowspan="1" colspan="1">95% CI for OR</th>
                        <th align="center" rowspan="1" colspan="1">P-value<xref ref-type="table-fn" rid="t004fn001"><sup>1</sup></xref></th>
                        <th align="center" rowspan="1" colspan="1">Inverse Odds Ratio</th>
                        <th align="center" rowspan="1" colspan="1">Family</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>TG.48.3.</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">10.79</td>
                        <td align="center" rowspan="1" colspan="1">2.11–55.27</td>
                        <td align="center" rowspan="1" colspan="1">0.296</td>
                        <td align="center" rowspan="1" colspan="1">0.09</td>
                        <td align="center" rowspan="1" colspan="1">Glycerides</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>SM.38.1.</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">0.10</td>
                        <td align="center" rowspan="1" colspan="1">0.02–0.63</td>
                        <td align="center" rowspan="1" colspan="1">0.006</td>
                        <td align="center" rowspan="1" colspan="1">10.00</td>
                        <td align="center" rowspan="1" colspan="1">Sphingolipids</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>AC.2.0.</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">9.26</td>
                        <td align="center" rowspan="1" colspan="1">1.96–43.73</td>
                        <td align="center" rowspan="1" colspan="1">0.008</td>
                        <td align="center" rowspan="1" colspan="1">0.11</td>
                        <td align="center" rowspan="1" colspan="1">Acylcarnitines</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>PC.O.38.6.</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">0.14</td>
                        <td align="center" rowspan="1" colspan="1">0.04–0.55</td>
                        <td align="center" rowspan="1" colspan="1">0.019</td>
                        <td align="center" rowspan="1" colspan="1">7.14</td>
                        <td align="center" rowspan="1" colspan="1">Phospholipids</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>SM.33.2.</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">0.15</td>
                        <td align="center" rowspan="1" colspan="1">0.03–0.70</td>
                        <td align="center" rowspan="1" colspan="1">0.299</td>
                        <td align="center" rowspan="1" colspan="1">6.67</td>
                        <td align="center" rowspan="1" colspan="1">Sphingolipids</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>TG.54.4.</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">6.53</td>
                        <td align="center" rowspan="1" colspan="1">1.34–31.90</td>
                        <td align="center" rowspan="1" colspan="1">0.128</td>
                        <td align="center" rowspan="1" colspan="1">0.15</td>
                        <td align="center" rowspan="1" colspan="1">Glycerides</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>Phe</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">6.45</td>
                        <td align="center" rowspan="1" colspan="1">1.52–27.44</td>
                        <td align="center" rowspan="1" colspan="1">0.006</td>
                        <td align="center" rowspan="1" colspan="1">0.16</td>
                        <td align="center" rowspan="1" colspan="1">Amino Acids</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>LPC.O.18.1.</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">0.16</td>
                        <td align="center" rowspan="1" colspan="1">0.04–0.66</td>
                        <td align="center" rowspan="1" colspan="1">0.003</td>
                        <td align="center" rowspan="1" colspan="1">6.25</td>
                        <td align="center" rowspan="1" colspan="1">Phospholipids</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>SM.37.1.</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">0.16</td>
                        <td align="center" rowspan="1" colspan="1">0.04–0.67</td>
                        <td align="center" rowspan="1" colspan="1">0.037</td>
                        <td align="center" rowspan="1" colspan="1">6.25</td>
                        <td align="center" rowspan="1" colspan="1">Sphingolipids</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">
                          <bold>SM.41.1.</bold>
                        </td>
                        <td align="center" rowspan="1" colspan="1">0.16</td>
                        <td align="center" rowspan="1" colspan="1">0.04–0.76</td>
                        <td align="center" rowspan="1" colspan="1">0.007</td>
                        <td align="center" rowspan="1" colspan="1">6.25</td>
                        <td align="center" rowspan="1" colspan="1">Sphingolipids</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="t004fn001">
                    <p><sup>1</sup>P-values obtained from models with continuous covariates. TG = triglyceride, SM = sphingomyelin, AC = acylcarnitine, PC = phosphatidylcholine, Phe = phenylalanine, LPC = lysophosphatidylcholine</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>Notably, several of the metabolites in <xref rid="pone.0247493.t004" ref-type="table">Table 4</xref> are from the same family. Four of these metabolites, for example, are in the sphingolipid family, which is notable since only 10% of the analyzed metabolites are from the sphingolipid family (S1 Table in <xref ref-type="supplementary-material" rid="pone.0247493.s001">S1 Appendix</xref>). Remaining metabolites include two each from the glyceride and phospholipid families. <xref ref-type="fig" rid="pone.0247493.g001">Fig 1</xref> demonstrates the log odds ratios of the 187 analyzed metabolites separated by metabolite family. The metabolites listed in <xref rid="pone.0247493.t004" ref-type="table">Table 4</xref> along with kynurenine and tryptophan are labeled in the plot. Values below 0 suggest that subjects with lower metabolite values have a greater chance of being a case. In particular, the vast majority of acylcarnitines, biogenic amines, and glycerides have positive log odds ratios. This suggests that metabolites from these families have similar associations with case-control status.</p>
              <fig id="pone.0247493.g001" orientation="portrait" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pone.0247493.g001</object-id>
                <label>Fig 1</label>
                <caption>
                  <title>Log odds ratios comparing the upper vs. lower tertile after adjusting for duration of symptoms and matching factors by metabolite family.</title>
                  <p>Referenced: Ten strongest odd ratios as well as Kynurenine and Tryptophan.</p>
                </caption>
                <graphic xlink:href="pone.0247493.g001"/>
              </fig>
            </sec>
            <sec sec-type="conclusions" id="sec013">
              <title>Discussion</title>
              <p>Infection with influenza is a major public health concern and currently there is no clear test or biomarker to identify individuals at risk for disease progression, such as respiratory failure or death. We have previously identified a strong association between metabolites involved in tryptophan metabolism and disease progression [<xref rid="pone.0247493.ref002" ref-type="bibr">2</xref>]. We have now extended these studies to include a broader metabolomic profile with biomarkers and metabolite families that are associated with disease progression.</p>
              <p>In this study we found a number a metabolomic families including individual metabolites associated with disease progression in influenza infection. We also noted that several of these metabolites were from the same family of metabolites. Amongst these families acylcarnitines, glycerides, sphingolipids, and biogenic amines had the strongest association based on our composite endpoint of death and/or respiratory failure.</p>
              <p>Acylcarnitines belong to a family of metabolites involved in fatty acid transport and certain plasma carnitines are elevated in insulin resistance [<xref rid="pone.0247493.ref014" ref-type="bibr">14</xref>]. Plasma acylcarnitines are also elevated in sepsis and have been shown to predict outcome. Specifically, Green and colleagues found that plasma acylcarnitines at the time of sepsis diagnosis differentiated survivors from non-survivors [<xref rid="pone.0247493.ref015" ref-type="bibr">15</xref>]. In our study, we found that diabetes was associated with the composite outcome of death or transfer to the ICU but not with acylcarnitine levels. The occurrence of sepsis was not associated with the composite outcome or acylcarnitine levels. Therefore, it is unknown if the acylcarnitine levels are unique to influenza infection and warrants further study.</p>
              <p>Sphingolipids were also altered in our subjects with severe influenza infection. Sphingolipids not only serve as structural components of the plasma membrane lipid bilayer but also participate in cell signaling. Much of what we know about sphingolipid signaling comes with the advent of advanced mass spectroscopy techniques that allow the simultaneous analysis and quantification of multiple sphingolipid species, such as we used in this study. Sphingolipid metabolites play key roles in immune cell migration and function [<xref rid="pone.0247493.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0247493.ref017" ref-type="bibr">17</xref>] and have been associated with sepsis and poor outcomes [<xref rid="pone.0247493.ref018" ref-type="bibr">18</xref>]. In addition, the pro-inflammatory cytokine TNF-α stimulates sphingolipid metabolism [<xref rid="pone.0247493.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0247493.ref013" ref-type="bibr">13</xref>]. In our INSIGHT cohort we reported elevated levels of TNF-α associated with disease progression following H1N1 infection [<xref rid="pone.0247493.ref001" ref-type="bibr">1</xref>] and in this subgroup we found an association of TNF-α with sphingolipid levels. In a ferret model of H1N1 respiratory tract infection the sphingolipid sphingomyelin correlated with viral titers [<xref rid="pone.0247493.ref005" ref-type="bibr">5</xref>]. Viral titers were unavailable for this analysis; therefore, we are unable to determine whether sphingolipid metabolism correlates with influenza titers. However, our finding of sphingolipid metabolism appears to primarily associate with progression to critical illness.</p>
              <p>We previously reported in this group that tryptophan metabolism is associated with disease progression as reflected by an increase in the kynurenine/tryptophan ratio [<xref rid="pone.0247493.ref002" ref-type="bibr">2</xref>]. In this current study our metabolomic profiling confirmed these previous measurements. When we focused on fatal cases, we found that the odds of death for low tryptophan levels were almost 26-fold higher. Induction of tryptophan metabolism has been demonstrated in both animal models and human infection with influenza [<xref rid="pone.0247493.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0247493.ref019" ref-type="bibr">19</xref>]. Similar to our findings, tryptophan and its main metabolic pathway have been associated with poor outcomes in inflammatory and infectious diseases [<xref rid="pone.0247493.ref020" ref-type="bibr">20</xref>–<xref rid="pone.0247493.ref022" ref-type="bibr">22</xref>].</p>
              <p>Lastly, we sought to determine if lung disease, such as COPD or asthma, was a confounder for tryptophan and its metabolite kynurenine. Viral infection, including influenza, is a common cause of COPD exacerbation and those with COPD have demonstrated worse outcomes with H1N1 infection [<xref rid="pone.0247493.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0247493.ref024" ref-type="bibr">24</xref>]. In addition, tryptophan metabolism through the kynurenine pathway is associated with COPD exacerbations [<xref rid="pone.0247493.ref025" ref-type="bibr">25</xref>, <xref rid="pone.0247493.ref026" ref-type="bibr">26</xref>]. However, in our small study we did not find lung disease to be a confounder for either the tryptophan metabolites or disease progression.</p>
            </sec>
            <sec sec-type="conclusions" id="sec014">
              <title>Conclusion</title>
              <p>In summary, a strength of this study is the demonstration of a metabolomic signature that associates with progression to death or respiratory failure in a relatively small case:control study of adults hospitalized with influenza A(H1N1)pdm09. This signature is enriched for metabolites with known associations to critical illness and poor outcomes. The results agree with our previous work [<xref rid="pone.0247493.ref005" ref-type="bibr">5</xref>] insofar as clear associations were found between kynurenine and the KT ratio and disease progression. In addition, low tryptophan levels are associated with a very high likelihood of death among those hospitalized for influenza. While this study has identified several classes of metabolites associated with poor outcome in the setting of A(H1N1)pdm09 infection, it is limited by the relatively small sample size as reflected by some large confidence intervals for some metabolites. Future studies could benefit from validating these findings in larger cohorts, other types/subtypes of influenza infection and include longitudinal testing to determine the durability of these signals.</p>
            </sec>
            <sec sec-type="supplementary-material" id="sec015">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="pone.0247493.s001">
                <label>S1 Appendix</label>
                <caption>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0247493.s001.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>We extend our grateful thanks to all the volunteers who have been participating in this study. INSIGHT <bold>International coordinating centers: Copenhagen:</bold> Bitten Aagaard, Álvaro H. D. Borges, Alessandro CozziLepri, Marius Eid, Per O. Jansson, Marianne Jeppesen, Zillah Maria Joensen, Ruth Kjærgaard Pedersen, Jens Lundgren, Birgit Riis Nielsen, Mary Pearson, Lars Peters, Tavs Qvist. <bold>London:</bold> Brian Angus, Abdel Babiker, Rachel Bennett, Nafisah Braimah, Yolanda Collaco-Moraes, Adam Cursley, Fleur Hudson, Sarah Pett, Charlotte Russell, Helen Webb. <bold>Sydney:</bold> Dianne Carey, David Courtney-Rodgers, Sean Emery, Pamela Shaw. <bold>Washington:</bold> Fred Gordin, Adriana Sanchez, Barbara Standridge, Michael Vjecha. <bold>Statistical and Data Management Center, Minneapolis, Minnesota:</bold> Kate Brekke, Megan Campbell, Eileen Denning, Alain DuChene, Nicole Engen, Michelle George, Merrie Harrison, James D. Neaton, Ray Nelson, Siu-Fun Quan, Terri Schultz, Deborah Wentworth. <bold>Specimen repositories and laboratories:</bold> John Baxter, Shawn Brown (Leidos Biomedical Research, Inc.), Marie Hoover (ABML). <bold>National Institute of Allergy and Infectious Disease/Leidos:</bold> John Beigel, Richard T. Davey Jr., Robin Dewar, Erin Gover, Rose McConnell, Julia Metcalf, Ven Natarajan, Tauseef Rehman, Jocelyn Voell.<bold>Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Westmead Hospital and University of Sydney, Westmead, New South Wales, Australia:</bold> Dominic E. Dwyer, Jen Kok. <bold>Centers for Disease Control and Prevention, Atlanta, Georgia:</bold> Timothy M. Uyeki. <bold>Community representative:</bold> David Munroe.</p>
              <p><bold>Clinical site investigators by country: Argentina</bold>: Damian Aguila, Maria Fernanda Alzogaray, Maria Fernanda Ballesteros, Laura Barcan, Laura Barcelona, Waldo Belloso, Veronica Berdiñas, Pablo Bonvehi, Juan Pablo Caeiro, Veronica Cisneros, Ana Crinejo, Daniel David, Luz Doldan, Juan Ebenrstejin, Flavio Lipari, Ana Lopardo, Gustavo Lopardo, Marcelo Losso, Pablo Lucchetti, Sergio Lupo, Laura Moreno Macias, Alejandra Moricz de Tesco, Analia Mykietiuk, Estaban Nannini, Gabriel Nieto, Laura Nieto, Luciana Peroni, Ignacio Retta, Patricia Rodriguez, Marisa Sanchez, Pablo Sanchez, Mariana de Paz Sierra, Silvina Tavella, Elena Temporiti, Liliana Trape, Ines Vieni, Eduardo Warley, Diego Yahni, Abel Humberto Zarate. <bold>Thailand</bold>: Anchalee Avihingsanon, Kanlaya Charoentonpuban, Ploenchan Chetchotisakd, Peeraporn Kaewon, Naphassanant Laopraynak, Weerawat Manosuthi, Kanitta Pussadee, Opass Putcharoen, Kiat Ruxrungtham, Gompol Suwanpimonkul, Sasiwimol Ubolyam. <bold>United States</bold>: Roberto Arduino, Barbara Atkinson, Taryn M. Aulicino, Jason V. Baker, Cindy Bardascino, Caitlin Bass, John D. Baxter, Mark Beilke, Beverly D. Bentley, Mary Lee Bertrand, Ann B. Brown, June Carbonneau, Richard Cindrich, Patty Coburn, Calvin J. Cohen, Linda Clark, Shirley Cummins, Paul Dassow, Jack A. DeHovitz, Nila J. Dharan, Leslie Faber, Marti Farrough, Matthew Freiberg, Edward Gardner, Kimberly Jo Garrett, Christiane Geisler, Marshall Glesby, Julia Green, Joanne Grenade, Edie Gunderson, John Gunter, Kirsis Ham, Susan Holman, Valery Hughes, Christopher Hurt, Mary Johnson, Glory Koerbel, Susan Koletar, Audrey Lan, Rodger MacArthur, Cheryl Marcus, Norm Markowitz, Maria Laura Martinez, Karen McLaughlin, Raquel Nahra, Mary Jane Nettles, Daniel Nixon, Richard Novak, Kathleen Nuffer, Hannah B. Olivet, Bola Omotosho, Armando P. Paez, Marta Paez-Quinde, Sonija Parker, Namrata Patil, Hari Polenakovik, Sandra Powell, Rachel A. Prosser, Nancy A. Reilly, Paul F. Riska, Stacey Rizza, Robert Schooley, Marla Schwarber, James Scott, Gary L. Simon, Jon Sivoravong, Daniel J. Skiest, Clemencia Solorzano, Rita Sondengam, Nicole Swanson, Ellen Tedaldi, Zelalem Temesgen, Doug Thomas, Bill Thron, Colleen Traverse, David E. Uddin, Daniel Z. Uslan, Marina Vasco, William M. Vaughan, Isabel Vecino, Barbara Wade, Catrice Walker, Kathy Watson, Vicky Watson, David Wohl, Cameron R. Wolfe. <bold>Belgium</bold>: Leslie Andry, Mireille Bielen, Nathan Clumeck, Eric Florence, Kabamba Kabeya, Jolanthe Sagaer, Jozef Weckx. <bold>Greece</bold>: Olga Anagnostou, Anastasia Antoniadou, George Daikos, Vicky Gioukari, Ioannis Kalomenidis, Maria Kantzanou, Georgios Koratzanis, Nikolaos Koulouris, Efstratios Maltezos, Symeon Metallidis, Vlassis Polixronopoulos, Helen Sambatakou, Athanasios Skoutelis, Giota Touloumi, Nikolaos Vasilopoulos. <bold>Australia</bold>: Mark Bloch, Nicky Cunningham, Dominic E. Dwyer, Sian Edwards, Julian Elliott, Jill Garlick, Philip Habel, Fiona Kilkenny, Helen Lau, Karen MacRae, John McBride, Richard Moore, Isabel Prone, Ristila Ram, Sue Richmond, Norm Roth, Tuck Meng Soo, Jo-Anne Thompson, Trina Vincent, Emanuel Vlakahis, Rachel Woolstencroft. <bold>United Kingdom</bold>: David Chadwick, Tristan Clarke, Jane Democratis, David Dockrell, Robert Heyderman, Ben Jeffs, Stefan Kutter, Martin Llewelyn, Jane Minton, Melanie Newport, Ashley Price. <bold>Peru</bold>: Carlos Benites, Raul Castillo, Romina Chinchay, Eva Cornelio, Maria Guevara, Luis Gutierrez, Jose Hidalgo, Alberto La Rosa, Yvett Pinedo, Maria Saenz, Juan Vega. <bold>Denmark</bold>: Bente Baadegaard, Karen Bach, Philippa Collins, Jan Gerstoft, Lene Hergens, Lene Pors Jensen, Zillah Maria Joensen, Gitte Kronborg, Iben Rose Loftheim, Henrik Nielsen, Lars Oestergaard, Court Pedersen, Jens Aage Stauning, Svend Stenvang Pedersen, Yordanos Yehdego. <bold>Germany</bold>: Frank Bergmann, Christoph Boesecke, Johannes R. Bogner, Norbert Brockmeyer, Christine Czaja-Harder, Rika Draenert, Gerd Fätkenheuer, Hartwig Klinker, Tim Kümmerle, Clara Lehmann, Vera Müller, Andreas Plettenberg, Jürgen Rockstroh, Stefan Schlabe, Wolfgang E. Schmidt, Dirk Schürmann, Gundolf Schüttfort, Ulrich Seybold, Christoph Stephan, Albrecht Stoehr, Klaus Tillmann, Susanne Wiebecke, Timo Wolf. <bold>Spain</bold>: Jose Arribas, Javier Carbone, Eduardo Fernández Cruz, David Dalmau, Vincente Estrada, Patricia Herrero, Hernando Knobel, Paco López, Rocío Montejano, José Sans Moreno, José Ramón Paño, Begoña Portas, Maria Rodrigo, Pilar Romero, Domingo Sánchez-Sendín, Vincente Soriano. <bold>Poland</bold>: Elzbieta Bakowska, Andrzej Jerzy Horban, Brygida Knysz, Karolina Pyziak Kowalska, Anna Zubkiewicz-Zarebska. <bold>Estonia</bold>: Kerstin Kase, Helen Mülle, Kai Zilmer. <bold>Chile</bold>: Gladys Allendes, Jimena Flores, Rebeka Northland, Carlos Perez, Isabel Velasco, Marcelo Wolff. <bold>China</bold>: Man-Yee Chu, Tak-chiu Wu. <bold>Austria</bold>: Heinz Burgmann, Selma Tobudic. <bold>Japan</bold>: Mayumi Imahashi, Junji Imamura, Yasumasa Iwatani, Ayumi Kogure, Masashi Nakahata, Wataru Sugiura, Yoshiyuki Yokomaku. <bold>Norway</bold>: Anne Maagaard.</p>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="pone.0247493.ref001">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>Davey</surname><given-names>RT</given-names><suffix>Jr</suffix></name>., <name><surname>Lynfield</surname><given-names>R</given-names></name>, <name><surname>Dwyer</surname><given-names>DE</given-names></name>, <name><surname>Losso</surname><given-names>MH</given-names></name>, <name><surname>Cozzi-Lepri</surname><given-names>A</given-names></name>, <name><surname>Wentworth</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>The association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studies</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>2</issue>):<fpage>e57121</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0057121</pub-id><?supplied-pmid 23468921?><pub-id pub-id-type="pmid">23468921</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Pett</surname><given-names>SL</given-names></name>, <name><surname>Kunisaki</surname><given-names>KM</given-names></name>, <name><surname>Wentworth</surname><given-names>D</given-names></name>, <name><surname>Griffin</surname><given-names>TJ</given-names></name>, <name><surname>Kalomenidis</surname><given-names>I</given-names></name>, <name><surname>Nahra</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study</article-title>. <source>Open Forum Infect Dis</source>. <year>2018</year>;<volume>5</volume>(<issue>1</issue>):<fpage>ofx228</fpage>. <pub-id pub-id-type="doi">10.1093/ofid/ofx228</pub-id><?supplied-pmid 29322062?><pub-id pub-id-type="pmid">29322062</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Yuka Torii</surname><given-names>YK</given-names></name>, <name><surname>Hajime</surname><given-names>Sato</given-names></name>, <name><surname>Kazunori</surname><given-names>Sasaki</given-names></name>, <name><surname>Tamaki</surname><given-names>Fujimori</given-names></name>, <name><surname>Kawada</surname><given-names>Jun-ichi</given-names></name>, <name><surname>Takikawa</surname><given-names>Osamu</given-names></name>, <etal>et al</etal>. <article-title>Quantitative metabolome profiling reveals the involvement of the kynurenine pathway in influenza-associated encephalopathy</article-title>. <source>Metabolomics</source>. <year>2016</year>;<volume>12</volume>:<fpage>84</fpage>:1–9.</mixed-citation>
              </ref>
              <ref id="pone.0247493.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Bowler</surname><given-names>RP</given-names></name>, <name><surname>Wendt</surname><given-names>CH</given-names></name>, <name><surname>Fessler</surname><given-names>MB</given-names></name>, <name><surname>Foster</surname><given-names>MW</given-names></name>, <name><surname>Kelly</surname><given-names>RS</given-names></name>, <name><surname>Lasky-Su</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>New Strategies and Challenges in Lung Proteomics and Metabolomics. An Official American Thoracic Society Workshop Report</article-title>. <source>Ann Am Thorac Soc</source>. <year>2017</year>;<volume>14</volume>(<issue>12</issue>):<fpage>1721</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1513/AnnalsATS.201710-770WS</pub-id>
<?supplied-pmid 29192815?><pub-id pub-id-type="pmid">29192815</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Tisoncik-Go</surname><given-names>J</given-names></name>, <name><surname>Gasper</surname><given-names>DJ</given-names></name>, <name><surname>Kyle</surname><given-names>JE</given-names></name>, <name><surname>Eisfeld</surname><given-names>AJ</given-names></name>, <name><surname>Selinger</surname><given-names>C</given-names></name>, <name><surname>Hatta</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Integrated Omics Analysis of Pathogenic Host Responses during Pandemic H1N1 Influenza Virus Infection: The Crucial Role of Lipid Metabolism</article-title>. <source>Cell Host Microbe</source>. <year>2016</year>;<volume>19</volume>(<issue>2</issue>):<fpage>254</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2016.01.002</pub-id>
<?supplied-pmid 26867183?><pub-id pub-id-type="pmid">26867183</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Chandler</surname><given-names>JD</given-names></name>, <name><surname>Hu</surname><given-names>X</given-names></name>, <name><surname>Ko</surname><given-names>EJ</given-names></name>, <name><surname>Park</surname><given-names>S</given-names></name>, <name><surname>Lee</surname><given-names>YT</given-names></name>, <name><surname>Orr</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Metabolic pathways of lung inflammation revealed by high-resolution metabolomics (HRM) of H1N1 influenza virus infection in mice</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source>. <year>2016</year>;<volume>311</volume>(<issue>5</issue>):<fpage>R906</fpage>–<lpage>R16</lpage>. <pub-id pub-id-type="doi">10.1152/ajpregu.00298.2016</pub-id>
<?supplied-pmid 27558316?><pub-id pub-id-type="pmid">27558316</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Cui</surname><given-names>L</given-names></name>, <name><surname>Fang</surname><given-names>J</given-names></name>, <name><surname>Ooi</surname><given-names>EE</given-names></name>, <name><surname>Lee</surname><given-names>YH</given-names></name>. <article-title>Serial Metabolome Changes in a Prospective Cohort of Subjects with Influenza Viral Infection and Comparison with Dengue Fever</article-title>. <source>J Proteome Res</source>. <year>2017</year>;<volume>16</volume>(<issue>7</issue>):<fpage>2614</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.7b00173</pub-id>
<?supplied-pmid 28560878?><pub-id pub-id-type="pmid">28560878</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Cui</surname><given-names>L</given-names></name>, <name><surname>Zheng</surname><given-names>D</given-names></name>, <name><surname>Lee</surname><given-names>YH</given-names></name>, <name><surname>Chan</surname><given-names>TK</given-names></name>, <name><surname>Kumar</surname><given-names>Y</given-names></name>, <name><surname>Ho</surname><given-names>WE</given-names></name>, <etal>et al</etal>. <article-title>Metabolomics Investigation Reveals Metabolite Mediators Associated with Acute Lung Injury and Repair in a Murine Model of Influenza Pneumonia</article-title>. <source>Sci Rep</source>. <year>2016</year>;<volume>6</volume>:<fpage>26076</fpage>. <pub-id pub-id-type="doi">10.1038/srep26076</pub-id><?supplied-pmid 27188343?><pub-id pub-id-type="pmid">27188343</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref009">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Izquierdo-Garcia</surname><given-names>JL</given-names></name>, <name><surname>Nin</surname><given-names>N</given-names></name>, <name><surname>Jimenez-Clemente</surname><given-names>J</given-names></name>, <name><surname>Horcajada</surname><given-names>JP</given-names></name>, <name><surname>Arenas-Miras</surname><given-names>MDM</given-names></name>, <name><surname>Gea</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Metabolomic Profile of ARDS by Nuclear Magnetic Resonance Spectroscopy in Patients With H1N1 Influenza Virus Pneumonia</article-title>. <source>Shock</source>. <year>2018</year>;<volume>50</volume>(<issue>5</issue>):<fpage>504</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1097/SHK.0000000000001099</pub-id>
<?supplied-pmid 29293175?><pub-id pub-id-type="pmid">29293175</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Banoei</surname><given-names>MM</given-names></name>, <name><surname>Vogel</surname><given-names>HJ</given-names></name>, <name><surname>Weljie</surname><given-names>AM</given-names></name>, <name><surname>Kumar</surname><given-names>A</given-names></name>, <name><surname>Yende</surname><given-names>S</given-names></name>, <name><surname>Angus</surname><given-names>DC</given-names></name>, <etal>et al</etal>. <article-title>Plasma metabolomics for the diagnosis and prognosis of H1N1 influenza pneumonia</article-title>. <source>Crit Care</source>. <year>2017</year>;<volume>21</volume>(<issue>1</issue>):<fpage>97</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-017-1672-7</pub-id><?supplied-pmid 28424077?><pub-id pub-id-type="pmid">28424077</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Wenk</surname><given-names>MR</given-names></name>. <article-title>The emerging field of lipidomics</article-title>. <source>Nat Rev Drug Discov</source>. <year>2005</year>;<volume>4</volume>(<issue>7</issue>):<fpage>594</fpage>–<lpage>610</lpage>. <pub-id pub-id-type="doi">10.1038/nrd1776</pub-id>
<?supplied-pmid 16052242?><pub-id pub-id-type="pmid">16052242</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>Clarke</surname><given-names>CJ</given-names></name>, <name><surname>Truong</surname><given-names>TG</given-names></name>, <name><surname>Hannun</surname><given-names>YA</given-names></name>. <article-title>Role for neutral sphingomyelinase-2 in tumor necrosis factor alpha-stimulated expression of vascular cell adhesion molecule-1 (VCAM) and intercellular adhesion molecule-1 (ICAM) in lung epithelial cells: p38 MAPK is an upstream regulator of nSMase2</article-title>. <source>J Biol Chem</source>. <year>2007</year>;<volume>282</volume>(<issue>2</issue>):<fpage>1384</fpage>–<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M609216200</pub-id>
<?supplied-pmid 17085432?><pub-id pub-id-type="pmid">17085432</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Hannun</surname><given-names>YA</given-names></name>, <name><surname>Obeid</surname><given-names>LM</given-names></name>. <article-title>Principles of bioactive lipid signalling: lessons from sphingolipids</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2008</year>;<volume>9</volume>(<issue>2</issue>):<fpage>139</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1038/nrm2329</pub-id>
<?supplied-pmid 18216770?><pub-id pub-id-type="pmid">18216770</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Schooneman</surname><given-names>MG</given-names></name>, <name><surname>Vaz</surname><given-names>FM</given-names></name>, <name><surname>Houten</surname><given-names>SM</given-names></name>, <name><surname>Soeters</surname><given-names>MR</given-names></name>. <article-title>Acylcarnitines: reflecting or inflicting insulin resistance?</article-title><source>Diabetes</source>. <year>2013</year>;<volume>62</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.2337/db12-0466</pub-id>
<?supplied-pmid 23258903?><pub-id pub-id-type="pmid">23258903</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref015">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>Green</surname><given-names>P</given-names></name>, <name><surname>Theilla</surname><given-names>M</given-names></name>, <name><surname>Singer</surname><given-names>P</given-names></name>. <article-title>Lipid metabolism in critical illness</article-title>. <source>Curr Opin Clin Nutr Metab Care</source>. <year>2016</year>;<volume>19</volume>(<issue>2</issue>):<fpage>111</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1097/MCO.0000000000000253</pub-id>
<?supplied-pmid 26828580?><pub-id pub-id-type="pmid">26828580</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Cyster</surname><given-names>JG</given-names></name>, <name><surname>Schwab</surname><given-names>SR</given-names></name>. <article-title>Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs</article-title>. <source>Annu Rev Immunol</source>. <year>2012</year>;<volume>30</volume>:<fpage>69</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-immunol-020711-075011</pub-id>
<?supplied-pmid 22149932?><pub-id pub-id-type="pmid">22149932</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref017">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>Rivera</surname><given-names>J</given-names></name>, <name><surname>Proia</surname><given-names>RL</given-names></name>, <name><surname>Olivera</surname><given-names>A</given-names></name>. <article-title>The alliance of sphingosine-1-phosphate and its receptors in immunity</article-title>. <source>Nat Rev Immunol</source>. <year>2008</year>;<volume>8</volume>(<issue>10</issue>):<fpage>753</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1038/nri2400</pub-id>
<?supplied-pmid 18787560?><pub-id pub-id-type="pmid">18787560</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref018">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>Neugebauer</surname><given-names>S</given-names></name>, <name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name>, <name><surname>Pelekanou</surname><given-names>A</given-names></name>, <name><surname>Marioli</surname><given-names>A</given-names></name>, <name><surname>Baziaka</surname><given-names>F</given-names></name>, <name><surname>Tsangaris</surname><given-names>I</given-names></name>, <etal>et al</etal>. <article-title>Metabolite Profiles in Sepsis: Developing Prognostic Tools Based on the Type of Infection</article-title>. <source>Crit Care Med</source>. <year>2016</year>;<volume>44</volume>(<issue>9</issue>):<fpage>1649</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0000000000001740</pub-id>
<?supplied-pmid 27097292?><pub-id pub-id-type="pmid">27097292</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref019">
                <label>19</label>
                <mixed-citation publication-type="journal"><name><surname>Holtze</surname><given-names>M</given-names></name>, <name><surname>Asp</surname><given-names>L</given-names></name>, <name><surname>Schwieler</surname><given-names>L</given-names></name>, <name><surname>Engberg</surname><given-names>G</given-names></name>, <name><surname>Karlsson</surname><given-names>H</given-names></name>. <article-title>Induction of the kynurenine pathway by neurotropic influenza A virus infection</article-title>. <source>Journal of neuroscience research</source>. <year>2008</year>;<volume>86</volume>(<issue>16</issue>):<fpage>3674</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.21799</pub-id>
<?supplied-pmid 18655201?><pub-id pub-id-type="pmid">18655201</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>MacKenzie</surname><given-names>CR</given-names></name>, <name><surname>Heseler</surname><given-names>K</given-names></name>, <name><surname>Muller</surname><given-names>A</given-names></name>, <name><surname>Daubener</surname><given-names>W</given-names></name>. <article-title>Role of indoleamine 2,3-dioxygenase in antimicrobial defence and immuno-regulation: tryptophan depletion versus production of toxic kynurenines</article-title>. <source>Curr Drug Metab</source>. <year>2007</year>;<volume>8</volume>(<issue>3</issue>):<fpage>237</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.2174/138920007780362518</pub-id>
<?supplied-pmid 17430112?><pub-id pub-id-type="pmid">17430112</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref021">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>Moffett</surname><given-names>JR</given-names></name>, <name><surname>Namboodiri</surname><given-names>MA</given-names></name>. <article-title>Tryptophan and the immune response</article-title>. <source>Immunology and cell biology</source>. <year>2003</year>;<volume>81</volume>(<issue>4</issue>):<fpage>247</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1046/j.1440-1711.2003.t01-1-01177.x</pub-id>
<?supplied-pmid 12848846?><pub-id pub-id-type="pmid">12848846</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref022">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Schmidt</surname><given-names>SV</given-names></name>, <name><surname>Schultze</surname><given-names>JL</given-names></name>. <article-title>New Insights into IDO Biology in Bacterial and Viral Infections</article-title>. <source>Front Immunol</source>. <year>2014</year>;<volume>5</volume>:<fpage>384</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2014.00384</pub-id><?supplied-pmid 25157255?><pub-id pub-id-type="pmid">25157255</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Louie</surname><given-names>JK</given-names></name>, <name><surname>Jean</surname><given-names>C</given-names></name>, <name><surname>Acosta</surname><given-names>M</given-names></name>, <name><surname>Samuel</surname><given-names>MC</given-names></name>, <name><surname>Matyas</surname><given-names>BT</given-names></name>, <name><surname>Schechter</surname><given-names>R</given-names></name>. <article-title>A review of adult mortality due to 2009 pandemic (H1N1) influenza A in California</article-title>. <source>PLoS One</source>. <year>2011</year>;<volume>6</volume>(<issue>4</issue>):<fpage>e18221</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0018221</pub-id><?supplied-pmid 21483677?><pub-id pub-id-type="pmid">21483677</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref024">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>Mallia</surname><given-names>P</given-names></name>, <name><surname>Johnston</surname><given-names>SL</given-names></name>. <article-title>Influenza infection and COPD</article-title>. <source>Int J Chron Obstruct Pulmon Dis</source>. <year>2007</year>;<volume>2</volume>(<issue>1</issue>):<fpage>55</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.2147/copd.2007.2.1.55</pub-id>
<?supplied-pmid 18044066?><pub-id pub-id-type="pmid">18044066</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref025">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>Maneechotesuwan</surname><given-names>K</given-names></name>, <name><surname>Kasetsinsombat</surname><given-names>K</given-names></name>, <name><surname>Wongkajornsilp</surname><given-names>A</given-names></name>, <name><surname>Barnes</surname><given-names>PJ</given-names></name>. <article-title>Decreased indoleamine 2,3-dioxygenase activity and IL-10/IL-17A ratio in patients with COPD</article-title>. <source>Thorax</source>. <year>2013</year>;<volume>68</volume>(<issue>4</issue>):<fpage>330</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1136/thoraxjnl-2012-202127</pub-id>
<?supplied-pmid 23255616?><pub-id pub-id-type="pmid">23255616</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0247493.ref026">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Meier</surname><given-names>MA</given-names></name>, <name><surname>Ottiger</surname><given-names>M</given-names></name>, <name><surname>Vogeli</surname><given-names>A</given-names></name>, <name><surname>Steuer</surname><given-names>C</given-names></name>, <name><surname>Bernasconi</surname><given-names>L</given-names></name>, <name><surname>Thomann</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Activation of the Serotonin Pathway is Associated with Poor Outcome in COPD Exacerbation: Results of a Long-Term Cohort Study</article-title>. <source>Lung</source>. <year>2017</year>;<volume>195</volume>(<issue>3</issue>):<fpage>303</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1007/s00408-017-0004-7</pub-id>
<?supplied-pmid 28434116?><pub-id pub-id-type="pmid">28434116</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
          <sub-article id="pone.0247493.r001" article-type="aggregated-review-documents">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0247493.r001</article-id>
              <title-group>
                <article-title>Decision Letter 0</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ratnasekhar</surname>
                    <given-names>Ch</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2021 Ch Ratnasekhar</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Ch Ratnasekhar</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article id="rel-obj001" ext-link-type="doi" xlink:href="10.1371/journal.pone.0247493" related-article-type="reviewed-article"/>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>Submission Version</meta-name>
                  <meta-value>0</meta-value>
                </custom-meta>
              </custom-meta-group>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">9 Feb 2021</named-content>
              </p>
              <p>Metabolite Profiles associated with Disease Progression in Influenza Infection</p>
              <p>PONE-D-20-32204</p>
              <p>Dear Dr. Chris,</p>
              <p>We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p>
              <p>Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p>
              <p>An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <ext-link ext-link-type="uri" xlink:href="http://www.editorialmanager.com/pone/">http://www.editorialmanager.com/pone/</ext-link>, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <email>authorbilling@plos.org</email>.</p>
              <p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email>onepress@plos.org</email>.</p>
              <p>Kind regards,</p>
              <p>Ch Ratnasekhar, Ph.D.</p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
              <p>Journal Requirements:</p>
              <p>1.Thank you for stating the following in the Competing Interests section:</p>
              <p>"I have read the journal's policy and the authors of this manuscript have the following competing interests: The views expressed in this article are those of the authors and do not reflect the views of the US Government, the National Institutes of Health, the Department of Veterans Affairs, the funders, or any of the authors’ affiliated academic institutions."</p>
              <p>Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: "This does not alter our adherence to  PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors <ext-link ext-link-type="uri" xlink:href="about:blank">http://journals.plos.org/plosone/s/competing-interests</ext-link>). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.</p>
              <p>Please respond by return email with your amended Competing Interests Statement and we will change the online submission form on your behalf.</p>
              <p>Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <ext-link ext-link-type="uri" xlink:href="about:blank">http://journals.plos.org/plosone/s/competing-interests</ext-link></p>
              <p>Additional Editor Comments (optional): I would suggest to submit the raw data in online public access platform like Metabolights or NIH public accession data sumbmission</p>
              <p>Reviewer comments</p>
              <p>Thanks for the opportunity to review this manuscript. I would like to submit my recommendation directly via email (as given below).</p>
              <p>My response is as follows -</p>
              <p>1. Recommend (Accept)</p>
              <p>2. Is the manuscript technically sound, and do the data support the conclusions? (YES)</p>
              <p>3. Has the statistical analysis been performed appropriately and rigorously? (Yes)</p>
              <p>4. Does the manuscript adhere to the PLOS Data Policy? (Yes) Expect for deposit of mass spectrometry data which I have recommended in my comments</p>
              <p>5. Is the manuscript presented in an intelligible fashion and written in standard English? (Yes)</p>
              <p>6. Review Comments to the Author: (Pasted below)</p>
              <p>7. Would you like your identity revealed to the authors of this submission? (Yes)</p>
              <p>8. Do you have any potentially competing interests? None</p>
              <p>Review Comments to the Author:</p>
              <p>In the manuscript titled as "Metabolite Profiles associated with Disease Progression in Influenza Infection” the authors report the identification of plasma metabolites that may be correlated with influenza disease progression. The cohort on which this study has been carried out is part of the INSIGHT Influenza Hospitalization study (FLU 003) which is focused on characterising the A(H1N1)pdm09 infection. Prior work as part of this study has revealed biomarkers as predictors of disease progression. In fact, as report by the authors, the same cohort samples used in this study have been analysed earlier for 2 metabolites - tryptophan (T) and kynurenine (K). The previous reported a significantly elevated KT ratio among cases whose clinical outcomes worsened following hospitalisation. The present study has been undertaken by the authors to followup on the earlier study and to find out if any other metabolites have any correlation with worsening disease outcome.</p>
              <p>In this study, the authors have used a quantitative Metabolomics approach to measure hundreds of metabolites to identify those associated with death or ICU treatment in patients hospitalised for influenza A(H1N1)pdm09 infection. The manuscript reports that the metabolite signature in disease survivors is different from that of those who develop severe disease. Particularly, the authors report that low levels of tryptophan is strongly associated with death. The study is designed and although the number of patients included in the study is small (small cohort size), the conclusion made are statistically significant.</p>
              <p>The Biocrates methodology and standards have been used in this study to rigorously analyse the metabolites from plasma samples. This is one of the best available technologies for conducting the quantitative metabolomics work undertaken. First, the authors were able to confirm their previous finding that low levels of tryptophan is strongly associated with death; mortality end point - OR 17.33 (95% CI, 1.60-187.76) &amp; ICU end point - OR 0.21 (95% CI, 0.02-2.70), respectively. The study also reports that two other groups of metabolites - acylcarnitines &amp; glycerides - which exhibited significant association with composite end point (both death &amp; ICU treatment), with OR 3.99 (95% CI, 1.03-15.42) pvalue 0.009 &amp; OR 3.69 (95% CI, 1.08-12.61) pvalue 0.020, respectively. However, they are not predictors of mortality. Other groups of metabolites such as biogenic amines and sphingolipids are reported to have better correlation with non-fatal cases.</p>
              <p>Further analysis on individual metabolites identified 10 that were significantly associated with composite end point. Interestingly, these metabolites are mainly form the sphingolipid, glyceride and phospholipid families. In summary, the authors conclude that acylcarnitines, glycerides, sphingolipids, and biogenic amines have the strongest association with the composite endpoint in this study. Primarily this study has helped to confirm and establish earlier findings that decreased tryptophan levels are highly correlated with death due to influenza.</p>
              <p>This study has demonstrated unequivocally that plasma metabolite signatures are valid biomarkers for disease progression in case of A(H1N1)pdm09 infection. Moreover this study also assumes significance in view of the current COVID19 pandemic, as identifying patients whose disease outcomes are likely to worsen is very important. The methodology laid out by this study is broadly applicable.</p>
              <p>One important point is that the authors will have to deposit the mass spec data generated from this study in a public repository (such as Metabolomics work bench) and provide the data deposit ID in the methods section.</p>
              <p>No corrections or changes recommended by this reviewer.</p>
              <p>Reviewers' comments:</p>
            </body>
          </sub-article>
          <sub-article id="pone.0247493.r002" article-type="editor-report">
            <front-stub>
              <article-id pub-id-type="doi">10.1371/journal.pone.0247493.r002</article-id>
              <title-group>
                <article-title>Acceptance letter</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ratnasekhar</surname>
                    <given-names>Ch</given-names>
                  </name>
                  <role>Academic Editor</role>
                </contrib>
              </contrib-group>
              <permissions>
                <copyright-statement>© 2021 Ch Ratnasekhar</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Ch Ratnasekhar</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <related-article id="rel-obj002" ext-link-type="doi" xlink:href="10.1371/journal.pone.0247493" related-article-type="reviewed-article"/>
            </front-stub>
            <body>
              <p>
                <named-content content-type="letter-date">25 Mar 2021</named-content>
              </p>
              <p>PONE-D-20-32204 </p>
              <p>Metabolite Profiles associated with Disease Progression in Influenza Infection </p>
              <p>Dear Dr. Wendt:</p>
              <p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. </p>
              <p>If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <email>onepress@plos.org</email>.</p>
              <p>If we can help with anything else, please email us at <email>plosone@plos.org</email>. </p>
              <p>Thank you for submitting your work to PLOS ONE and supporting open access. </p>
              <p>Kind regards, </p>
              <p>PLOS ONE Editorial Office Staff</p>
              <p>on behalf of</p>
              <p>Dr. Ch Ratnasekhar </p>
              <p>Academic Editor</p>
              <p>PLOS ONE</p>
            </body>
          </sub-article>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
